Arlinda Rezhdo

Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function. We’re seeing success across a range of soluble and hard-to-drug membrane proteins including a Claudin and a GPCR. We’ve extensively tested these designs in our wet lab and included detailed data and controls, providing the first clear demonstration of how de novo design could expand the scope and efficiency of therapeutic antibody discovery. 🧵 Technical report: …bla-public.s3.us-east-1.amazonaws.com/2024_Nabla_JAM… Blog: nabla.bio/news/denovo

Design, Construction, and Validation of a Yeast-Displayed Chemically Expanded Antibody Library ift.tt/PZ1l4NJ #biorxiv_synbio

I’m speaking today at @PEGSboston, 5:10 pm, Eng Antibodies. Talk will cover new “solMPMP” tech from @nablabio where we use generative ML to create soluble proxies of valuable multipass membrane protein drug targets, and use these proxies to facilitate design of new biologics.

@SurgeBiswas will be giving a podium talk at PEGS Boston (bit.ly/4dG1SYD) tomorrow sharing some promising results in opening up these difficult targets. Go check it out

Excited to share @nablabio is partnering with 3 of the world’s largest pharma cos to use integrated AI and wet-lab tech to design antibodies against challenging disease targets. Thrilled to also add @radicalvcfund who led our $26M Series A to the family! bit.ly/4dDk4lP

🔥 Hot new #ProteinEngineering article by Rezhdo et al. where they show us how to screen for *inhibitory antibodies by yeast display! Read more at #PEDS academic.oup.com/peds/article/d…

Can you tell we are a proud lab? @Van_DeventerJim